This study is for people with severe asthma and high eosinophil levels. Eosinophils are a type of white blood cell involved in asthma symptoms. The study will last 12 months and looks at the safety and effectiveness of a medicine called GSK3511294 (Depemokimab). You can join if you completed treatment in previous related studies (206713 or 213744).

Key Points:

• The study lasts for 12 months.
• Participants must have completed previous studies 206713 or 213744.
• Not suitable for people with certain health issues like heart problems or active infections.

Before joining, you should understand the study's requirements and risks. Some people may not be eligible if they have certain medical conditions, are currently pregnant, or are taking other investigational drugs. It's important to talk to your doctor to see if this study is right for you and if it could help manage your asthma symptoms.